Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call
03:00pm, Thursday, 21'st Nov 2024
Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acon
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock
10:45am, Thursday, 21'st Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
10:45am, Wednesday, 20'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SAN RAFAEL, Calif. , Nov. 16, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO®
BioMarin to Participate in Three Upcoming Investor Conferences
08:00am, Wednesday, 06'th Nov 2024
UBS Global Healthcare Conference on November 12 at 11:00 am PST Jefferies London Healthcare Conference on November 19 at 9:00 am GMT 7th Annual Evercore ISI HealthCONx Conference on December 4 at
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 05'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Monday, 04'th Nov 2024
BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin (BMRN) Upgraded to Buy: Here's Why
01:01pm, Monday, 04'th Nov 2024
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BMRN vs. INCY: Which Stock Is the Better Value Option?
12:46pm, Monday, 04'th Nov 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is th
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
10:50am, Monday, 04'th Nov 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BioMarin Q3 Earnings & Revenues Beat Estimates, '24 Guidance Raised
12:10pm, Wednesday, 30'th Oct 2024
BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.
BioMarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Call Transcript
08:26pm, Tuesday, 29'th Oct 2024
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
07:35pm, Tuesday, 29'th Oct 2024
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
06:20pm, Tuesday, 29'th Oct 2024
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago.
Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During th
